Communiqués CStone Pharmaceuticals

Actions

2616

KYG2588M1006

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:08:05 02/07/2024			Varia. 5j.	Varia. 1 janv.
1,14 ^HKD	0,00%		+4,59%	-49,78%

18/06	CStone Pharmaceuticals annonce un changement de secrétaire général conjoint	CI
13/06	CStone obtient le feu vert pour la fabrication locale d'AYVAKIT en Chine	MT

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

CStone to Present CS5001 Phase I Results at 2024 ASCO Annual Meeting	06/05	AQ
CStone sells to Servier its exclusive rights to TIBSOVO in Greater China and Singapore	22/12	AQ
CStone Announces NMPA Approval of Sugemalimab as First-line Treatment for Esophageal Squamous Cell Carcinoma	11/12	AQ
CStone Announces Oral Presentation of Registrational Trial Data from Sugemalimab in First-Line Gastric or Gastroesophageal Junction Adenocarcinoma at ESMO 2023	03/10/23	AQ
CStone Announces NMPA Approval of the AYVAKIT Companion Diagnostic Kit Developed in Partnership with Genetron	28/09/23	AQ
CStone Announces Publication of First-in-Human Study Results of Anti-PD-1 Antibody Nofazinlimab in British Journal of Cancer and Update of Global Phase III Trial of Nofazinlimab in HCC	25/09/23	AQ
CStone Announces Registrational Trial of Sugemalimab in First-line Gastric or Gastroesophageal Junction Adenocarcinoma Met Primary Endpoint of Overall Survival	30/08/23	AQ
CStone Pharmaceuticals Reports 2023 Interim Results and Updates	16/08/23	AQ
CStone Presents Results from Phase 3 Study of Sugemalimab in First-Line Esophageal Squamous Cell Carcinoma at ESMO GI 2023	30/06/23	AQ
CStone announces GAVRETO sNDA approval by China NMPA for first-line treatment of patients with locally advanced or metastatic RET fusion-positive non-small cell lung cancer	27/06/23	AQ
CStone Announces Publication in Nature Cancer Highlighting the Overall Survival Results of Sugemalimab in Non-Small Cell Lung Cancer	16/06/23	AQ
CStone Announces Oral Presentation at ESMO World GI 2023 for Pivotal Phase 3 Clinical Study of Sugemalimab in First-Line Esophageal Squamous Cell Carcinoma	13/06/23	AQ
CStone's Partner Servier presents positive new TIBSOVO data for IDH1-mutated acute myeloid leukemia at ASCO	07/06/23	AQ
CStone's Partner Blueprint Medicines Announces FDA Approval of AYVAKIT for Adults with Indolent Systemic Mastocytosis	05/06/23	AQ
CStone's Partner Servier to Present TIBSOVO Clinical Data at ASCO 2023 and EHA 2023	29/05/23	AQ
CStone announces first patient enrollment in China for the multi-regional phase 1 trial of CS5001, a potential best-in-class ROR1-targeting ADC	24/04/23	AQ
CStone announces China's NMPA has accepted the supplemental biologics license application for sugemalimab as a first-line treatment for esophageal squamous cell carcinoma	06/04/23	AQ
CStone Announces Publication of GEMSTONE-201 Study Results for Sugemalimab Monotherapy in the Treatment of Relapsed, Refractory Extranodal NK/T-Cell Lymphoma in Journal of Clinical Oncology	31/03/23	AQ
CStone Announces Oral Presentation of Translational Data for CS5001, A Potentially Best-in-Class ROR1-Targeting ADC, at the 13th World ADC London Conference	20/03/23	AQ
CStone announces China's NMPA has accepted the supplementary new drug application of sugemalimab as first-line treatment for patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma	28/02/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués CStone Pharmaceuticals

Actions

2616

KYG2588M1006

Communiqués

Filtres